A Multimodal Intervention Program to Improve Sexual Health and Self-perceived Quality of Life in Patients Treated for Cervical Cancer (PROVIDENCE)
Study Details
Study Description
Brief Summary
The PROVIDENCE Trial aims to explore the improvement of sexual health and self-perceived health related quality of life (measured by Patient Reported Outcome Measures) through a multimodal intervention that includes patient education on healthy habits and the prevention of vaginal dysfunction using vaginal moisturizers and topical estrogens. To achieve this, a randomized design is proposed to assess sexual health and quality of life in patients treated for cervical cancer who undergo this intervention compared to those who receive standard care.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
Cervical cancer treatment, both radical hysterectomy and chemoradiotherapy, can impair all scopes of daily life and, beyond the physical changes caused by treatment, has psychological and social implications that influence health-related quality of life (HR-QoL). Patients undergoing treatment for cervical cancer have shown to score less in HR-QoL scales compared to healthy women. More than half of women with gynecological cancer experience sexual dysfunction, especially those affected by cervical cancer. In spite of the latest 2023 ESGO/ESTRO/ESP recommendations on the management of cervical cancer, several observational studies indicate that the percentage of cervical cancer patients receiving information and treatment for early menopause and sexual dysfunction, especially regarding hormone replacement therapy, does not exceed 50%.
The PROVIDENCE trial is a multi-institutional, national, randomized clinical trial which aims to demonstrate that a multimodal intervention including patient education on sexuality and healthy habits and the prevention of vaginal dysfunction reduces sexual disfunction and HR-QoL impairment in patients treated for cervical cancer. The recruitment period is scheduled from January 2024 to December 2026 and will be held in Gynecology Oncology Units of referral hospitals in Spain.
Patients will be randomized 1:1 at diagnosis of cervical cancer to control arm or intervention arm. After treatment for initial or locally advanced cervical cancer, patients in the control arm will undergo the standard follow-up and treatment of post-treatment morbidity will be performed following the standard procedures as determined by their referring physician. The proposed multimodal intervention for patients assigned to the intervention group (detailed below) includes education on healthy habits, the prevention of vaginal dysfunction using vaginal moisturizers and topical estrogens, and a systematic evaluation of the need of hormone replacement therapy.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Multimodal Intervention Group Multimodal Intervention on sexual dysfunction and quality-of-life after treatment for cervical cancer: application of topical vaginal estrogens, systematic evaluation of the need of systemic hormone replacement therapy (and treatment if needed), application of hormone-free vaginal-vulvar moisturizing cream containing hyaluronic acid, use of a vaginal vibrator twice a week for 5 to 10 minutes each time with the help of intimate lubricant, access to online informational content about sexuality, access to online informational content about nutrition, access to online informational content about sports, access to online informational content about lifestyle habits |
Combination Product: Multimodal intervention on sexual dysfunction and quality-of-life
Multimodal intervention includes education on healthy habits, the prevention of vaginal dysfunction using vaginal moisturizers and topical estrogens, and a systematic evaluation of the need of hormone replacement therapy.
|
| No Intervention: Standard Care Group Standard follow-up in Gynecological Oncology Units of participating centers after treatment for cervical cancer |
Outcome Measures
Primary Outcome Measures
- FSFI score [12 months after completion of primary treatment for cervical cancer]
global score in FSFI (Female Sexual Function Index) questionnaire
Secondary Outcome Measures
- FSFI (6 months) [6 months after completion of primary treatment for cervical cancer]
global score in FSFI (Female Sexual Function Index) questionnaire
- EORTC QLQ-30 [12 months after completion of primary treatment for cervical cancer]
global score in EORTC (European Organisation for Research and Treatment of Cancer) QLQ-30 questionnaire
- EORTC QLQ-30 (6 months) [6 months after completion of primary treatment for cervical cancer]
global score in EORTC QLQ-30 questionnaire
- EORTC Cx-24 (6 months) [6 months after completion of primary treatment for cervical cancer]
global score in EORTC Cx-24 questionnaire
- EORTC Cx-24 [12 months after completion of primary treatment for cervical cancer]
global score in EORTC Cx-24 questionnaire
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Women older that 18 years, with initial or locally advanced primary cervical cancer
-
Squamous, adenocarcinoma or adenosquamous histology
-
Stage I-III cervical cancer treated with surgery and/or radiotherapy ± systemic treatment in - Gynecology Oncology Units of referral hospitals in Spain
-
Signed informed consent by the patient or legal guardian
Exclusion Criteria:
-
Women younger tan 18 years
-
Pregnancy or breastfeeding
-
Patients with intraepithelial lesions of cervix uteri without invasive disease
-
Metastatic tumor in the cervix uteri or primary tumor with atypical histology
-
Inability to complete the questionnaires included in the study protocol
-
Contraindications for the use of topical vaginal estrogens
-
Patients undergoing fertility-preservation treatment (conization or trachelectomy)
-
Patients undergoing palliative treatment
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hospital Clínic de Barcelona | Barcelona | Spain | 08036 | |
| 2 | Hospital Universitario 12 de Octubre | Madrid | Spain | 28041 |
Sponsors and Collaborators
- Hospital Clinic of Barcelona
- Hospital Universitario 12 de Octubre
Investigators
- Study Director: Blanca Gil-Ibáñez, MD, PhD, Hospital Universitario 12 de Octubre
- Study Director: Berta Díaz-Feijoo, MD, PhD, Hospital Clinic of Barcelona
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PROVIDENCE